6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and PBPK Modeling Approaches

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          This white paper examines recent progress, applications and challenges in predicting unbound and total tissue and intra/subcellular drug concentrations using in vitro and preclinical models, imaging techniques and physiologically-based pharmacokinetic (PBPK) modeling. Published examples, regulatory submissions and case studies illustrate the application of different types of data in drug development to support modeling and decision making for compounds with transporter-mediated disposition, and likely disconnects between tissue and systemic drug exposure. The goals of this manuscript are to illustrate current best practices and outline practical strategies for selecting appropriate in vitro and in vivo experimental methods to estimate or predict tissue and plasma concentrations, and to use these data in the application of PBPK modeling for human PK, efficacy and safety assessment in drug development.

          Related collections

          Author and article information

          Contributors
          Journal
          0372741
          3058
          Clin Pharmacol Ther
          Clin. Pharmacol. Ther.
          Clinical pharmacology and therapeutics
          0009-9236
          1532-6535
          31 July 2018
          12 September 2018
          November 2018
          01 November 2019
          : 104
          : 5
          : 865-889
          Affiliations
          [1 ]Investigational Drug Disposition, Eli Lilly and Company, Lilly Corporate Center, DC0714, Indianapolis, IN 46285, USA; Tel: 317-277-4324
          [2 ]Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Kenilworth, New Jersey 07033, USA; 732-594-0977
          [3 ]Pharmaceutical Sciences, Pharmaceutical Research and Early Development, Roche Innovation Centre Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, CH-4070 Basel, Switzerland
          [4 ]Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, CB #7569 Kerr Hall, Chapel Hill, NC 27599-7569, USA; Tel: (919) 962-7030
          [5 ]Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, USA; 301-796-1541
          [6 ]Temple University School of Pharmacy, Department of Pharmaceutical Sciences, 3307 N Broad Street, Philadelphia PA 19140, USA; 215-707-9110
          [7 ]Department of Pharmacy, Uppsala University, Box 580, SE-75123 Uppsala, Sweden +46-(0)18-471 46 30
          [8 ]Safety and ADME Translational Sciences, Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca R&D, Cambridge CB4 0WG, UK
          [9 ]Department of Pharmacokinetics, Dynamics and Metabolism, Janssen R&D, Beerse, Belgium; Tel: +32-14606812
          [10 ]Sugiyama Laboratory, RIKEN Innovation Center, RIKEN Research Cluster for Innovation, Yokohama 230-0045, Japan; Tel: (045) 506-1814
          [11 ]Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Kenilworth, New Jersey 07033, USA; 908-464-2375
          [12 ]Department of Pharmaceutics, University of Washington, Seattle, WA, USA; 206-685-2869
          [13 ]Centre for Applied Pharmacokinetic Research, School of Health Sciences, The University of Manchester, Manchester M13 9PT, UK; + 44-161-275-6886
          Author notes
          [* ]Corresponding author: Dr Aleksandra Galetin, Centre for Applied Pharmacokinetic Research, School of Health Sciences, The University of Manchester, Stopford Building, Oxford Road, Manchester, M13 9PT, UK, Tel: (+) 44 161 275 6886; Aleksandra.Galetin@ 123456manchester.ac.uk

          Collaborators: Eef Hoeben Quantitative Sciences, Janssen R&D, Beerse, Belgium

          Dapeng Chen, Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Boston, MA 02115, USA

          Georgy Hartmann, Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Kenilworth, NJ 07033, USA

          Karsten Menzel, Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., West Point, PA 19486, USA

          Article
          PMC6197917 PMC6197917 6197917 nihpa983569
          10.1002/cpt.1183
          6197917
          30059145
          c2a126b3-c3fb-4c44-965c-e3dcce528714
          History
          Categories
          Article

          Distribution,Drug Development,Drug-Drug Interactions,Drug Transport,In Vitro,Imaging,In-vitro in-vivo correlation,Transporters,Physiology-based pharmacokinetics

          Comments

          Comment on this article